Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYLINE-LTE: Long-term Extension Study in Ulcerative Colitis
NCT07652294Phase 2Enrolling by invitation
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Jun 2026
- Primary completion
- Mar 2029
- Countries
- 23
01
Overview
A Phase 2 trial of SPY001, SPY002, SPY003 in ulcerative colitis (UC), sponsored by Spyre Therapeutics, Inc.. Started Jun 2026; status: enrolling by invitation.
02
Drugs
SPY001SPY002SPY003
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07652294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652294.